에스티팜

237690KOSDAQ

52.5 / 100

Reference Date: 2026-09-08

Financial Score20.0 / 40

News Sentiment19.5 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 8.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

ESTEPAF, originally established as Samcheonri Pharmaceutical in 1983 and later acquired by Dong-A Ssosiogroup in 2010, has expanded into the oligonucleotide CDMO sector, achieving global top 3 production capacity. It entered the mRNA business in 2020, completed the second oligo facility in 2025, and is advancing clinical trials for its self-developed drugs STP0404 (HIV treatment) and STP1002 (cancer treatment). The company has integrated CRO and CDMO services into a one-stop system, enhancing its pharmaceutical development capabilities through global partnerships.

Number of Employees

1,560people

Average Salary

68.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

33.89Industry Average 15.000.0Point

2.3x industry avg (risky)

PBR

3.23Industry Average 1.200.0Point

2.7x industry avg (risky)

ROE

9.96Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

4.18Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲40.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 7.4% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 1Negative 0Average Sentiment Score 78

Positive
[인사이드 스토리]암백신 뭐길래…모더나 '면역 경비시스템' 베팅
개인맞춤형 mRNA 백신 임상 성공으로 에스티팜의 암백신 기술이 주목받고 있어 긍정적 영향 기대.
Positive
IBK투자證 “모더나, mRNA 암백신 3상 첫 성공… 알테오젠·에스티...
IBK투자증권 분석에 따르면 모더나의 mRNA 암백신 성공이 알테오젠과 에스티팜의 CDMO 수혜 가능성을 높여 에스티팜의 주가에 긍정적 영향을 미칠 것으로 예상됩니다.
Positive
에스티팜, '차세대 RNA' 국제 심포지엄 개최
에스티팜이 차세대 RNA 기술을 주제로 국제 심포지엄을 개최하여 국내 RNA 산업 활성화에 기여할 것으로 기대됩니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 91,700Won52-week high 168,70052-week low 84,700

1-month return1.0Point

1m -8.39% (falling)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral반기보고서 (2026.06)2026-08-14
Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-08-11